|
시장보고서
상품코드
1807691
세계의 종양 기반 분자진단약 시장 규모, 점유율, 동향, 업계 분석 : 제품별, 유형별, 기술별, 지역별 - 시장 예측(2025-2034년)Oncology Based Molecular Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Type, By Technology, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 종양 기반 분자진단약 시장 규모는 2034년까지 61억 2,000만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
종양 기반 분자진단은 암과 관련된 유전자 및 분자의 변화를 해독하여 정확한 임상적 의사결정을 유도하는 첨단 툴입니다. 종양 기반 분자진단 시장은 정밀 종양학(Precision Oncology)에 대한 관심이 높아짐에 따라 분자학적 지식을 활용하여 개별 종양 프로파일에 따라 치료 전략을 조정하기 위한 분자진단 시장이 확대되고 있습니다. 이러한 추세는 일반적인 치료법에서 효능을 높이고 부작용을 최소화하는 표적치료제로의 전환이라는 암 치료의 광범위한 변화를 반영하고 있습니다. 이러한 맞춤형 솔루션에 대한 수요 증가는 지속적인 기술 혁신과 표준 종양학 워크플로우에 분자진단약물의 통합을 촉진하고 있습니다.
수술 없이도 실시간 모니터링과 조기 발견이 가능한 액체생검과 같은 비침습적 진단 기술의 채택이 증가하고 있는 것도 성장 기회 확대에 기여하고 있습니다. 이러한 발전으로 질병의 진행과 치료 반응을 역동적으로 평가할 수 있게 되어 분자진단약물의 임상적 유용성이 확대되고 있습니다. 의료진들은 저침습적이고 정확한 진단을 통해 환자의 예후를 개선하기 위해 노력하고 있으므로 이러한 기술의 개발과 활용은 앞으로도 종양학 진단의 최전선에서 계속될 것으로 예측됩니다.
종양 기반 분자진단 시장 : 분석 개요
제품별로는 PCR, 시퀀싱, 하이브리데이션 등 다양한 분자진단 및 검사에 필수적인 시약 부문이 58.61%의 매출 점유율로 시장을 주도했습니다.
기술별로는 상세하고 고해상도의 암 유전체 지식을 제공할 수 있는 시퀀싱 분야가 가장 빠르게 성장할 것으로 예측됩니다.
북미는 첨단 의료 인프라, 탄탄한 연구 생태계, 혁신적인 진단 기술의 조기 도입에 힘입어 2024년 세계 점유율 44.69%를 차지하며 종양 기반 분자진단 의약품 시장을 독점했습니다.
아시아태평양 시장은 지원적인 규제, 높은 진단 기준, 맞춤형 암 치료에 대한 수요 증가에 힘입어 예측 기간 중 가장 빠르게 성장할 것으로 예측됩니다.
세계의 종양 기반 분자진단약시장에서 주요 기업에는 Artivion, Inc., Aroa Oncology Based Molecular Diagnostics, B. Braun SE, Baxter, BD, INTEGRA LIFESCIENCES, Johnson &Johnson Services, Inc., Medtronic, Pfizer Inc., Sanofi, Stryker 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 분석 방법
제4장 세계의 종양 기반 분자진단약 시장 인사이트
- 시장 스냅숏
- 종양 기반 분자진단약 시장 역학
- 촉진요인과 기회
- 세계 각국에서 암 발증률·이환율의 상승
- 분자 종양 검사 기술의 진보
- 억제요인과 과제
- 높은 연구개발비와 운영 비용
- 여론과 프라이버시에 관한 판례
- 촉진요인과 기회
- PESTEL 분석
- 종양 기반 분자진단약 시장의 동향
- 밸류체인 분석
제5장 세계의 종양 기반 분자진단약시장 : 유형별
- 주요 분석 결과
- 서론
- 유방암
- 전립선암
- 대장암
- 자궁경부암
- 간암
- 폐암
- 혈액암
- 신장암
- 기타
제6장 세계의 종양 기반 분자진단약시장 : 제품별
- 주요 분석 결과
- 서론
- 기기
- 시약
- 기타
제7장 세계의 종양 기반 분자진단약시장 : 기술별
- 주요 분석 결과
- 서론
- PCR
- in situ 하이브리다이제이션
- INAAT
- 칩·마이크로어레이
- 질량분석
- 시퀀싱
- TMA
- 기타
제8장 세계의 종양 기반 분자진단약시장 : 지역별
- 주요 분석 결과
- 서론
- 종양 기반 분자진단약 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 유형별(2020-2034년)
- 북미 : 제품별(2020-2034년)
- 북미 : 기술별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 유형별(2020-2034년)
- 유럽 : 제품별(2020-2034년)
- 유럽 : 기술별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 유형별(2020-2034년)
- 아시아태평양 : 제품별(2020-2034년)
- 아시아태평양 : 기술별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 유형별(2020-2034년)
- 중동 및 아프리카 : 제품별(2020-2034년)
- 중동 및 아프리카 : 기술별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 유형별(2020-2034년)
- 라틴아메리카 : 제품별(2020-2034년)
- 라틴아메리카 : 기술별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Abbott
- Bayer AG
- BD
- Cepheid
- Agilent Technologies, Inc.
- Danaher
- Hologic, Inc.
- Qiagen
- F. Hoffmann-La Roche Ltd.
- Siemens
- Sysmex
The oncology-based molecular diagnostics market size is expected to reach USD 6.12 billion by 2034, according to a new study by Polaris Market Research. The report "Oncology Based Molecular Diagnostics Market Share, Size, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Type, By Technology, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Oncology-based molecular diagnostics are advanced tools that decode cancer-related genetic and molecular alterations to guide precise clinical decision-making. The oncology-based molecular diagnostics market is expanding due to the growing focus on precision oncology, where molecular insights are increasingly being used to tailor treatment strategies based on individual tumor profiles. This trend reflects a broader transformation in cancer care, moving from generalized therapies to targeted approaches that improve efficacy and minimize adverse effects. The growing demand for such personalized solutions is driving continuous innovation and integration of molecular diagnostics into standard oncology workflows.
The increasing adoption of noninvasive diagnostic techniques, such as liquid biopsy, which offer real-time monitoring and early detection without the need for surgical procedures, further contributes to the growth opportunities. These advancements are expanding the clinical utility of molecular diagnostics by enabling dynamic assessment of disease progression and treatment response. The development and utilization of such technologies are expected to remain at the forefront of the oncology diagnostics landscape as healthcare providers seek to enhance patient outcomes through minimally invasive and highly accurate diagnostics.
Oncology Based Molecular Diagnostics Market Report Highlights
In terms of product, the reagents segment led the market with 58.61% revenue share, as they are essential for various molecular diagnostic tests such as PCR, sequencing, and hybridization.
Based on technology, the sequencing segment is projected to grow the fastest due to its ability to deliver detailed, high-resolution cancer genomic insights.
North America dominated the oncology molecular diagnostics market with a 44.69% global share in 2024, supported by advanced healthcare infrastructure, a robust research ecosystem, and early adoption of innovative diagnostic technologies.
Asia Pacific market is expected to grow the fastest during the forecast period, fueled by supportive regulations, high diagnostic standards, and rising demand for personalized cancer care.
A few global key players in the oncology based molecular diagnostics market include Artivion, Inc.; Aroa Oncology Based Molecular Diagnostics; B. Braun SE; Baxter; BD; INTEGRA LIFESCIENCES; Johnson & Johnson Services, Inc.; Medtronic; Pfizer Inc.; Sanofi; and Stryker.
Polaris Market Research has segmented the oncology based molecular diagnostics market report on the basis of type, product, technology, and region:
By Type Outlook (Revenue, USD Billion, 2020-2034)
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Others
By Product Outlook (Revenue, USD Billion, 2020-2034)
Instruments
Reagents
Others
By Technology Outlook (Revenue, USD Billion, 2020-2034)
PCR
In situ hybridization
INAAT
Chips and microarrays
Mass spectrometry
Sequencing
TMA
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Oncology Based Molecular Diagnostics Market Insights
- 4.1. Oncology Based Molecular Diagnostics Market - Market Snapshot
- 4.2. Oncology Based Molecular Diagnostics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Incidence and Prevalence of Cancer Globally
- 4.2.1.2. Rising Advancement in Molecular Oncology Tests Technology
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High R&D and operational costs
- 4.2.3. Public opinion and privacy legal precedents
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Oncology Based Molecular Diagnostics Market Trends
- 4.6. Value Chain Analysis
5. Global Oncology Based Molecular Diagnostics Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 5.3. Breast Cancer
- 5.3.1. Global Oncology Based Molecular Diagnostics Market, by Breast Cancer, by Region, 2020-2034 (USD Billion)
- 5.4. Prostate Cancer
- 5.4.1. Global Oncology Based Molecular Diagnostics Market, by Prostate Cancer, by Region, 2020-2034 (USD Billion)
- 5.5. Colorectal Cancer
- 5.5.1. Global Oncology Based Molecular Diagnostics Market, by Colorectal Cancer, by Region, 2020-2034 (USD Billion)
- 5.6. Cervical Cancer
- 5.6.1. Global Oncology Based Molecular Diagnostics Market, by Cervical Cancer, by Region, 2020-2034 (USD Billion)
- 5.7. Liver Cancer
- 5.7.1. Global Oncology Based Molecular Diagnostics Market, by Liver Cancer, by Region, 2020-2034 (USD Billion)
- 5.8. Lung Cancer
- 5.8.1. Global Oncology Based Molecular Diagnostics Market, by Lung Cancer, by Region, 2020-2034 (USD Billion)
- 5.9. Blood Cancer
- 5.9.1. Global Oncology Based Molecular Diagnostics Market, by Blood Cancer, by Region, 2020-2034 (USD Billion)
- 5.10. Kidney Cancer
- 5.10.1. Global Oncology Based Molecular Diagnostics Market, by Kidney Cancer, by Region, 2020-2034 (USD Billion)
- 5.11. Others
- 5.11.1. Global Oncology Based Molecular Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global Oncology Based Molecular Diagnostics Market, by Product
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 6.3. Instruments
- 6.3.1. Global Oncology Based Molecular Diagnostics Market, by Instruments, by Region, 2020-2034 (USD Billion)
- 6.4. Reagents
- 6.4.1. Global Oncology Based Molecular Diagnostics Market, by Reagents, by Region, 2020-2034 (USD Billion)
- 6.5. Others
- 6.5.1. Global Oncology Based Molecular Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Oncology Based Molecular Diagnostics Market, by Technology
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 7.3. PCR
- 7.3.1. Global Oncology Based Molecular Diagnostics Market, by PCR, by Region, 2020-2034 (USD Billion)
- 7.4. In situ hybridization
- 7.4.1. Global Oncology Based Molecular Diagnostics Market, by In situ hybridization, by Region, 2020-2034 (USD Billion)
- 7.5. INAAT
- 7.5.1. Global Oncology Based Molecular Diagnostics Market, by INAAT, by Region, 2020-2034 (USD Billion)
- 7.6. Chips and microarrays
- 7.6.1. Global Oncology Based Molecular Diagnostics Market, by Chips and microarrays, by Region, 2020-2034 (USD Billion)
- 7.7. Mass spectrometry
- 7.7.1. Global Oncology Based Molecular Diagnostics Market, by Mass spectrometry, by Region, 2020-2034 (USD Billion)
- 7.8. Sequencing
- 7.8.1. Global Oncology Based Molecular Diagnostics Market, by Sequencing, by Region, 2020-2034 (USD Billion)
- 7.9. TMA
- 7.9.1. Global Oncology Based Molecular Diagnostics Market, by TMA, by Region, 2020-2034 (USD Billion)
- 7.10. Others
- 7.10.1. Global Oncology Based Molecular Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
8. Global Oncology Based Molecular Diagnostics Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Oncology Based Molecular Diagnostics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Oncology Based Molecular Diagnostics Market - North America
- 8.3.1. North America: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.3.3. North America: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.3.4. Oncology Based Molecular Diagnostics Market - US
- 8.3.4.1. US: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.3.4.2. US: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.3.4.3. US: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.3.5. Oncology Based Molecular Diagnostics Market - Canada
- 8.3.5.1. Canada: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4. Oncology Based Molecular Diagnostics Market - Europe
- 8.4.1. Europe: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.3. Europe: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.4. Oncology Based Molecular Diagnostics Market - UK
- 8.4.4.1. UK: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.5. Oncology Based Molecular Diagnostics Market - France
- 8.4.5.1. France: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.5.2. France: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.5.3. France: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.6. Oncology Based Molecular Diagnostics Market - Germany
- 8.4.6.1. Germany: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.7. Oncology Based Molecular Diagnostics Market - Italy
- 8.4.7.1. Italy: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.8. Oncology Based Molecular Diagnostics Market - Spain
- 8.4.8.1. Spain: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.9. Oncology Based Molecular Diagnostics Market - Netherlands
- 8.4.9.1. Netherlands: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.10. Oncology Based Molecular Diagnostics Market - Russia
- 8.4.10.1. Russia: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.4.11. Oncology Based Molecular Diagnostics Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5. Oncology Based Molecular Diagnostics Market - Asia Pacific
- 8.5.1. Asia Pacific: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.4. Oncology Based Molecular Diagnostics Market - China
- 8.5.4.1. China: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.4.2. China: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.4.3. China: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.5. Oncology Based Molecular Diagnostics Market - India
- 8.5.5.1. India: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.5.2. India: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.5.3. India: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.6. Oncology Based Molecular Diagnostics Market - Malaysia
- 8.5.6.1. Malaysia: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.7. Oncology Based Molecular Diagnostics Market - Japan
- 8.5.7.1. Japan: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.8. Oncology Based Molecular Diagnostics Market - Indonesia
- 8.5.8.1. Indonesia: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.9. Oncology Based Molecular Diagnostics Market - South Korea
- 8.5.9.1. South Korea: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.10. Oncology Based Molecular Diagnostics Market - Australia
- 8.5.10.1. Australia: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.5.11. Oncology Based Molecular Diagnostics Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.6. Oncology Based Molecular Diagnostics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.6.4. Oncology Based Molecular Diagnostics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.6.5. Oncology Based Molecular Diagnostics Market - UAE
- 8.6.5.1. UAE: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.6.6. Oncology Based Molecular Diagnostics Market - Israel
- 8.6.6.1. Israel: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.6.7. Oncology Based Molecular Diagnostics Market - South Africa
- 8.6.7.1. South Africa: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.6.8. Oncology Based Molecular Diagnostics Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.7. Oncology Based Molecular Diagnostics Market - Latin America
- 8.7.1. Latin America: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.7.4. Oncology Based Molecular Diagnostics Market - Mexico
- 8.7.4.1. Mexico: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.7.5. Oncology Based Molecular Diagnostics Market - Brazil
- 8.7.5.1. Brazil: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.7.6. Oncology Based Molecular Diagnostics Market - Argentina
- 8.7.6.1. Argentina: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
- 8.7.7. Oncology Based Molecular Diagnostics Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Oncology Based Molecular Diagnostics Market, by Type, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Oncology Based Molecular Diagnostics Market, by Product, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Oncology Based Molecular Diagnostics Market, by Technology, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Bayer AG
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. BD
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Cepheid
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Agilent Technologies, Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Danaher
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Hologic, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Qiagen
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. F. Hoffmann-La Roche Ltd.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Siemens
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Sysmex
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
